According to two sources who have seen the lab results, China’s CoronaVac, its COVID-19 vaccine, developed by Sinovac Biotech, has a general efficacy of less than 60% in clinical trial in Brazil.

Brazil’s Sao Paulo’s Butantan biomedical center, which has partnered with Sinovac to produce the vaccine in Brazil, plans on releasing the general efficacy of the test results of China’s CoronaVac, as it seeks emergency use for the shot from health regulator Anvisa.

Categories: Creativity, Entrepreneurship, HR & Organization, Strategy, Sustainability

Tags: Anvisa, Brazil, Butantan biomedical center, China, Chinese, clinical trial, CoronaVac, COVID-19, COVID19, emergency usage, emergency use, general efficacy, health regulator, partnered, partship, produce, production, Sao Paulo, Sinovac, Sinovac Biotech, test results, vaccine